Loading clinical trials...

COMPLETEDNA

MyDiaText Text Messaging Intervention for Diabetes

MyDiaText: Texting the Way to Better Diabetes Control

NCT02927639•Children's Hospital of Philadelphia

Summary

To test a text messaging intervention using MyDiaText and financial incentives to determine whether such an intervention will improve self-reported self-care behaviors in children 12 to 18 years old. The intervention will consist of daily text messages sent to the subject's personal mobile device. Subjects will be incentivized to respond to text messages via a lottery financial incentive. Previously developed text messages based on the American Diabetes Association (ADA) behavior goals will be used for this intervention.

Eligibility

Age

12 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of type 1 diabetes for more than 1 year
•HbA1c greater than or equal to 8% but less than 14%.
•Have been seen in diabetes clinic in the last 6 months
•Owns a personal mobile device with unlimited text messaging plan

Exclusion Criteria

•Non-English speaking
•Significant cognitive disability or major organ illness
•Hemolytic anemia

Locations (1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

July 31, 2018

Primary Completion Date

October 1, 2019

Completion Date

October 1, 2019

Last Updated

June 9, 2021

Enrollment

166

ACTUAL participants

Conditions

Diabetes Mellitus, Type 1

Interventions

MyDiaText

OTHER

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

NCT04786262

Diabetes Mellitus, Type 1Impaired Hypoglycemic Awareness+1 more

View study

RECRUITINGNA

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

NCT06748963

Diabetes Mellitus, Type 1

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MyDiaText Text Messaging Intervention for Diabetes

Inclusion Criteria

Exclusion Criteria

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Closed Loop and Education for Hypoglycemia Awareness Restoration

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Achieving Health in Emerging Adults With Diabetes (AHEAD) Program: A Clinical Trial Designed to Understand if Participation in a Clinical Program Developed Specifically to Support Emerging Adults With Type 1 Diabetes Leads to Improved Diabetes Outcomes.

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes